Last reviewed · How we verify
NCT06754436
Population Pharmacokinetics of L-AmB in Chinese Patients Assisted by Extracorporeal Membrane Pulmonary Oxygenation (ECMO)
Phase 4 trial testing Determination of blood drug concentration in Invasive Fungal Infections in 30 participants. Not yet recruiting.
11 November 2025
Quick facts
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 10 January 2025 |
| Primary completion | 11 November 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Determination of blood drug concentration — full drug profile →
Conditions studied
- Invasive Fungal Infections — all drugs for Invasive Fungal Infections →
- Liposomal Amphotericin B — all drugs for Liposomal Amphotericin B →
Sponsor
Beijing Anzhen Hospital
Who can join
18 and older, any sex, with Invasive Fungal Infections or Liposomal Amphotericin B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to investigate the effects of ECMO-assisted therapy on L-AmB PK parameters in patients with critically ill patients of invasive fungal infections, and to determine the in vivo pharmacokinetic changes of L-AmB in the ECMO population. To establish and validate a population pharmacokinetic model for liposomal amphotericin B in patients with critically ill patients of invasive fungal infections treated with ECMO adjuvant therapy, and to explore the pharmacokinetics/pharmacodynamics of the drug with different dosing regimens.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06754436
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Invasive Fungal Infections
Currently open trials in the same condition.
- NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
- NCT05688592 — Usefulness of PET-CT for Invasive Fungal Infection · recruiting
- NCT05750706 — Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative · recruiting
- NCT06103331 — Fungal Surveillance in Bangladesh · recruiting
Other Beijing Anzhen Hospital trials
Trials by the same sponsor.
- NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
- NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
- NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06754436 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
- Last refreshed: 31 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06754436.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing